GlassScriptPhysician profile
Stephen R Cooley
NPI 1306304704
$15,042.40
in general payments reported to CMS, 2019-2025
28 companies · $3,182 in 2025
The $3,182 reported for 2025 was more than what 97% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,929 · 2022: $3,192 · 2023: $3,245 · 2024: $3,494 · 2025: $3,182.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,906 · Education: $15.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,905.74 |
| Education | $15.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,891.81 | 2021-2025 | |
| Janssen Biotech, INC. | $1,281.79 | 2021-2025 | Tremfya, Na |
| Incyte Corporation | $1,274.96 | 2021-2025 | Opzelura, Iclusig |
| Genzyme Corporation | $1,013.85 | 2021-2025 | |
| Leo Pharma INC. | $929.24 | 2021-2025 | Adbry, Anzupgo, Spevigo |
| Arcutis Biotherapeutics, INC. | $816.01 | 2023-2025 | Zoryve |
| Novartis Pharmaceuticals Corporation | $723.45 | 2021-2025 | |
| Sun Pharmaceutical Industries INC. | $638.97 | 2021-2025 | Winlevi, Blu-U |
| E.R. Squibb & Sons, L.L.C. | $576.74 | 2022-2025 | Sotyktu |
| Amgen INC. | $552.61 | 2021-2025 | Otezla, Otezla |
| Regeneron Healthcare Solutions, INC. | $475.24 | 2021-2025 | Dupixent |
| Janssen Scientific Affairs, LLC | $435.24 | 2022-2024 | Tremfya |
| Lilly USA, LLC | $405.97 | 2021-2025 | Taltz, Olumiant, Ebglyss |
| Pfizer INC. | $382.65 | 2021-2024 | |
| Galderma Laboratories, L.P. | $361.07 | 2021-2025 | Nemluvio, Epsolay, Twyneo |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $329.92 | 2021-2025 | Bimzelx |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $297.62 | 2021-2025 | Jublia, Cabtreo, Arazlo |
| Dermavant Sciences, INC. | $221.87 | 2023-2024 | Vtama |
| Organogenesis INC. | $85.19 | 2021-2023 | Puraply |
| Botanix Sb INC | $71.12 | 2025 | Sofdra |
| Almirall LLC | $62.49 | 2024-2025 | Klisyri, Seysara |
| Helsinn Therapeutics (U.S.), INC. | $54.77 | 2021-2023 | Valchlor |
| Organon LLC | $41.19 | 2025 | Vtama |
| Strata Skin Sciences, INC. | $31.41 | 2025 | Xtrac |
| Vyne Pharmaceuticals INC. | $28.23 | 2021 | |
| Fresenius Kabi USA, LLC | $27.44 | 2023 | Idacio |
| Biofrontera INC. | $18.47 | 2024 | Xepi, Bf-Rhodoled, Ameluz |
| Epi Health, LLC | $13.08 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Cooley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.